Tumor-Infiltrating Podoplanin+ Fibroblasts Predict Worse Outcome in Solid Tumors

Background/Aims: Tumor-infiltrating fibroblasts are a heterogeneous population, and different subpopulations play differential roles in tumor microenvironment. However, the prognostic role of podoplanin+ fibroblasts in human solid tumors still remains controversial. Therefore, we performed the meta-analysis to better understand the role of this subpopulation in prognosis prediction for patients with solid tumor. Methods: We searched PubMed and EBSCO to identify the studies evaluating the association of intratumoral podoplanin+ fibroblast density detected by immunohistochemical method and overall survival (OS) and/or disease-free survival (DFS) in patients with solid tumor, then computed extracted data into hazard ratios for OS, DFS and clinicopathological features with STATA 12.0. Results: A total of 4883 patients from 29 published studies were incorporated into this meta-analysis. We found that podoplanin+ fibroblast infiltration significantly decreased OS and DFS in all types of solid tumors. In stratified analyses, podoplanin+ fibroblast infiltration was significantly associated with worse OS in cholangiocarcinoma, breast, lung and pancreatic cancer. And these cells were inversely associated with DFS in breast, lung and pancreatic cancer. In addition, high density of these cells significantly correlated with unfavorable clinicopathological features such as lymph node metastasis, TNM stage, lymphatic and vascular invasion of solid tumor. Conclusion: Podoplanin+ fibroblast infiltration leads to worse clinical outcome in solid tumors, implicating that it is a valuable prognostic biomarker and targeting it may have a potential for effective treatment.

Download Full-text

Prognostic significance of NEK2 in human solid tumors: a systematic review and meta-analysis

Bioscience Reports ◽

10.1042/bsr20180618 ◽

2019 ◽

Vol 39 (1) ◽

Cited By ~ 1

Author(s):

Xichen Wang ◽

Kang Chen ◽

Haipeng Liu ◽

Zeping Huang ◽

Xiao Chen ◽

...

Keyword(s):

Solid Tumors ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Pooled Analysis ◽

Prognostic Role ◽

Free Survival ◽

Hazard Ratios ◽

Human Solid Tumors

AbstractA consensus about the prognostic role of NIMA-related kinase 2 (NEK2) expression in various solid tumors has not been made yet. Thus, this meta-analysis aimed to systematically assess the prognostic role of NEK2 expression in patients with solid tumors. The eligible studies were identified through searching PubMed, Web of Science, and EMBASE. The hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) were used to evaluate the link between NEK2 overexpression and overall survival (OS) and disease-free survival/recurrence-free survival (DFS/RFS) of patients with solid tumors. A total of 17 studies with 4897 patients were included in this meta-analysis. Among these studies, all of them explored the association between NEK2 expression and OS of patients with solid tumors. Our pooled analysis indicated that NEK2 overexpression was significantly related to adverse OS (HR = 1.66; 95% CI: 1.38–2.00; P = 0.001). Additionally, there were six studies with 854 patients that investigated the association between NEK2 expression and DFS/RFS. Our pooled result indicated that there was a substantial relationship between NEK2 overexpression and poorer DFS/RFS (HR = 2.00; 95% CI: 1.61–2.48; P = 0.003). In conclusion, our meta-analysis indicated that NEK2 may be a useful predictor of prognosis and an effective therapeutic target in solid tumors. Nevertheless, more high-quality studies are warranted to further support our conclusions because of several limitations in our meta-analysis.

Download Full-text

Preoperative Platelet to Lymphocyte Ratio as a Prognostic Factor for Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

Digestive Surgery ◽

10.1159/000508444 ◽

2020 ◽

Vol 37 (6) ◽

pp. 447-455

Author(s):

Romualdas Riauka ◽

Povilas Ignatavicius ◽

Giedrius Barauskas

Keyword(s):

Systematic Review ◽

Pancreatic Cancer ◽

Prognostic Factor ◽

Meta Analysis ◽

Disease Free Survival ◽

Platelet To Lymphocyte Ratio ◽

Resectable Pancreatic Cancer ◽

Lymphocyte Ratio ◽

Asian Patients ◽

Hazard Ratios

Introduction: Various inflammatory markers have been investigated for a prognostic role in patients with resectable pancreatic cancer. However, the value of preoperative platelet to lymphocyte ratio (PLR) remains controversial. We performed a systematic review and meta-analysis of PLR as a preoperative prognostic factor for resectable pancreatic cancer. Material and Methods: Systematic literature search was conducted for studies assessing PLR influence as a preoperative prognostic factor in resectable pancreatic cancer patients. Random-effects model was applied for pooling hazard ratios and 95% confidence intervals related to overall survival (OS) and disease-free survival (DFS). Results: Fourteen articles with 2,743 patients were included in the study. According to the analysis, high PLR had no correlation with decreased OS. Due to high heterogeneity among studies, subgroup analysis was performed. Better OS was associated with low PLR in Asian patients, patients with mixed type of operation performed, and patients with preoperative PLR ≤150. Low PLR was associated with significantly better DFS. Conclusions: PLR is a predictive factor of better DFS in patients with resectable pancreatic cancer. However, available evidence does not support PLR as a reliable prognostic factor for OS.

Download Full-text

Clinical and prognostic role of Vasohibin-1 expression in solid tumors: An evidence from a meta-analysis

10.21203/rs.3.rs-19931/v1 ◽

2020 ◽

Author(s):

Ye Tian ◽

Chenkui Miao ◽

Xiaohan Ren ◽

Aiming Xu ◽

Shenhao Zhu ◽

...

Keyword(s):

Solid Tumors ◽

Fixed Effects ◽

Meta Analysis ◽

Relevant Literature ◽

Disease Free Survival ◽

Venous Invasion ◽

Tumor Grade ◽

Tumor Stage ◽

Clinicopathological Parameters

Abstract Background The role of Vasohibin-1 (VASH1) expression in solid tumors remains controversial. We thus performed this meta-analysis to elucidate the associations between VASH1 expression and the prognosis of solid tumors. Methods We searched relevant literature in PubMed, Web of Science and EMBASE. The hazard ratio (HR) or odds ratio (OR) and 95% confidence intervals (CIs) were measured by fixed-effects or random-effects models. Publication bias was assessed using funnel plots and Egger's regression test. Results The results showed that VASH1 expression exhibited a significantly decreased overall survival (OS) time (HR = 1.85; 95% Cl = 1.27–2.69) and disease-free survival (DFS) (HR = 1.80; 95% Cl = 1.41–2.29) time. Meanwhile, VASH1 expression was found significantly associated with TNM stage (OR = 1.96; 95% CI = 1.57–2.46), tumor stage (OR = 2.35; 95% CI = 1.88–2.93), lymph node metastasis (OR = 2.02; 95% CI = 1.37–2.98), venous invasion (OR = 1.63; 95% CI = 1.00-2.65), tumor grade (OR = 1.74; 95% CI = 1.13–2.67) and microvessel density (MVD) (OR = 4.30; 95% CI = 2.31–8.03). However, no significant association was found between the VASH1 expression and distant metastasis (OR = 1.81; 95% Cl = 0.74–1.41). Conclusion This study demonstrated that VASH1 expression was relevant to more aggressive clinicopathological parameters and might predict inferior DFS and OS in solid tumor patients.

Download Full-text

Clinical and Prognostic Role of Vasohibin-1 Expression in Solid Tumors

10.21203/rs.3.rs-72202/v1 ◽

2020 ◽

Author(s):

Ye Tian ◽

Chenkui Miao ◽

Xiaohan Ren ◽

Aiming Xu ◽

Shenhao Zhu ◽

...

Keyword(s):

Solid Tumors ◽

Fixed Effects ◽

Meta Analysis ◽

Relevant Literature ◽

Disease Free Survival ◽

Venous Invasion ◽

Tumor Grade ◽

Tumor Stage ◽

Clinicopathological Parameters

Abstract BackgroundThe role of Vasohibin-1 (VASH1) expression in solid tumors remains controversial. We thus performed this meta-analysis to elucidate the associations between VASH1 expression and the prognosis of solid tumors.MethodsWe searched relevant literature in PubMed, Web of Science and EMBASE. The hazard ratio (HR) or odds ratio (OR) and 95% confidence intervals (CIs) were measured by fixed-effects or random-effects models. Publication bias was assessed using funnel plots and Egger's regression test.ResultsThe results showed that VASH1 expression exhibited a significantly decreased overall survival (OS) time (HR = 1.85; 95% Cl = 1.27-2.69) and disease-free survival (DFS) (HR = 1.80; 95% Cl = 1.41-2.29) time. Meanwhile, VASH1 expression was found significantly associated with TNM stage (OR = 1.96; 95% CI = 1.57-2.46), tumor stage (OR = 2.35; 95% CI = 1.88-2.93), lymph node metastasis (OR = 2.02; 95% CI = 1.37-2.98), venous invasion (OR = 1.63; 95% CI = 1.00-2.65), tumor grade (OR = 1.74; 95% CI = 1.13-2.67) and microvessel density (MVD) (OR = 4.30; 95% CI = 2.31-8.03). However, no significant association was found between the VASH1 expression and distant metastasis (OR = 1.81; 95% Cl = 0.74-1.41). ConclusionThis study demonstrated that VASH1 expression was relevant to more aggressive clinicopathological parameters and might predict inferior DFS and OS in solid tumor patients.

Download Full-text

MCT4 has a potential to be used as a prognostic biomarker - a systematic review and meta-analysis

Oncology Reviews ◽

10.4081/oncol.2019.403 ◽

2019 ◽

Vol 13 (2) ◽

Cited By ~ 3

Author(s):

Arslaan Javaeed ◽

Sanniya Khan Ghauri

Keyword(s):

Systematic Review ◽

Cancer Progression ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Prognostic Indicators ◽

Future Research ◽

Tissue Samples ◽

Hazard Ratios

The role of several metabolic changes, such as hypoxia and acidosis, in the tumour environment has caught the attention of researchers in cancer progression and invasion. Lactate transport is one of the acidosis-enhancing processes that are mediated via monocarboxylate transporters (MCTs). We conducted a systematic review and meta-analysis to investigate the expression of two cancer-relevant MCTs (MCT1 and MCT4) and their potential prognostic significance in patients with metastasis of different types of cancer. Studies were included if they reported the number of metastatic tissue samples expressing either low or high levels of MCT1 and/or MCT4 or those revealing the hazard ratios (HRs) of the overall survival (OS) or disease-free survival (DFS) as prognostic indicators. During the period between 2010 and 2018, a total of 20 articles including 3831 patients (56.3% males) were identified. There was a significant association between MCT4 expression (high versus low) and lymph node metastasis [odds ratio (OR)=1.87, 95% confidence interval (CI)=1.10-3.17, P=0.02] and distant metastasis (OR=2.18, 95%CI=1.65-2.86, P<0.001) and the correlation remained significant for colorectal and hepatic cancer in subgroup analysis. For survival analysis, patients with shorter OS periods exhibited a higher MCT4 expression [hazard ratio (HR)=1.78, 95%CI=1.49-2.13, P<0.001], while DFS was shorter in patients with high MCT1 (HR=1.48, 95%CI=1.04-2.10, P=0.03) and MCT4 expression (HR=1.70, 95%CI=1.19-2.42, P=0.003) when compared to their counterparts with low expression levels. Future research studies should consider the pharmacologic inhibition of MCT4 to effectively inhibit cancer progression to metastasis.

Download Full-text

Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis

Cancer Cell International ◽

10.1186/s12935-020-1094-5 ◽

2020 ◽

Vol 20 (1) ◽

Cited By ~ 3

Author(s):

Jiawen Zhao ◽

Weijia Huang ◽

Yongxian Wu ◽

Yihuan Luo ◽

Bo Wu ◽

...

Keyword(s):

Systematic Review ◽

Solid Tumors ◽

Clinical Outcomes ◽

Lymphocyte Count ◽

Meta Analysis ◽

Progression Free Survival ◽

Prognostic Impact ◽

Cancer Type ◽

Hazard Ratios

Abstract Background To evaluate the prognostic value of pretreatment lymphocyte counts with respect to clinical outcomes in patients with solid tumors. Methods Systematic literature search of electronic databases (Pubmed, Embase and Web of Science) up to May 1, 2018 was carried out by two independent reviewers. We included Eligible studies assessed the prognostic impact of pretreatment lymphocytes and had reported hazard ratios (HR) with 95% confidence intervals (CIs) for endpoints including overall survival (OS) and progression-free survival (PFS). Only English publications were included. Results A total of 42 studies comprising 13,272 patients were included in this systematic review and meta-analysis. Low pretreatment lymphocyte count was associated with poor OS (HR = 1.27, 95% CI 1.16–1.39, P < 0.001, I2 = 58.5%) and PFS (HR = 1.27, 95% CI 1.15–1.40, P < 0.001, I2 = 25.7%). Subgroup analysis disaggregated by cancer type indicated that low pretreatment lymphocytes were most closely associated with poor OS in colorectal cancer followed by breast cancer and renal cancer. Conclusions Low pretreatment lymphocyte count may represent an unfavorable prognostic factor for clinical outcomes in patients with solid tumors.

Download Full-text

Prognostic role of DEK in human solid tumors: a meta-analysis

Oncotarget ◽

10.18632/oncotarget.19684 ◽

2017 ◽

Vol 8 (58) ◽

pp. 98985-98992

Author(s):

Gang Liu ◽

Disheng Xiong ◽

Junjie Zeng ◽

Guoxing Xu ◽

Rui Xiao ◽

...

Keyword(s):

Solid Tumors ◽

Meta Analysis ◽

Prognostic Role ◽

Human Solid Tumors

Download Full-text

The Clinicopathologic and Prognostic Significance of c-Myc Expression in Hepatocellular Carcinoma: A Meta-Analysis

Frontiers in Bioinformatics ◽

10.3389/fbinf.2021.706835 ◽

2021 ◽

Vol 1 ◽

Author(s):

Zhao Min ◽

Zhang Xunlei ◽

Chen Haizhen ◽

Zhao Wenjing ◽

Yu Haiyan ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Publication Bias ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Cochrane Library ◽

Poor Overall Survival ◽

Hazard Ratios ◽

Incidence And Mortality

Background: The incidence and mortality rates of hepatocellular carcinoma (HCC) are increasing worldwide. Therefore, there is an urgent need to elucidate the molecular drivers of HCC for potential early diagnosis and individualized treatment. Whether c-Myc expression plays a role in the clinicopathology and prognosis of patients with HCC remains controversial. This meta-analysis aimed to survey the prognostic role of c-Myc in HCC.Methods: We searched PubMed, Cochrane Library, Embase, Web of Science, and Google Scholar databases for studies published through March 2020 that examined the association between c-Myc expression and clinicopathology or prognosis in HCC patients. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to investigate the prognostic significance of c-Myc expression. Odds ratios were calculated to evaluate the association between c-Myc expression and clinicopathologic features. We also tested for publication bias.Results: Our meta-analysis included nine studies with 981 patients with HCC published between 1999 and 2016. A meta-analysis of these studies demonstrated that high c-Myc expression indicated a poor overall survival (OS) (HR = 2.260, 95% CI: 1.660–3.080, and p < 0.001) and disease-free survival (DFS) (HR = 1.770, 95% CI: 1.430–2.450, and p < 0.001) in patients with HCC. However, high c-Myc expression was not associated with HBsAg, pathological type, TNM stage, or cirrhosis. We did not find any significant publication bias among the included studies, indicating that our estimates were robust and reliable.Conclusion: c-Myc overexpression could predict poor OS and DFS in HCC patients. c-Myc could be a useful prognostic biomarker and therapeutic target for HCC.

Download Full-text

The Prognostic Role of Micro-RNAs in Head and Neck Cancers: An Umbrella Review

Journal of Personalized Medicine ◽

10.3390/jpm11080821 ◽

2021 ◽

Vol 11 (8) ◽

pp. 821

Author(s):

Marco Mariani ◽

Carolina Castagna ◽

Stefania Boccia ◽

Roberta Pastorino

Keyword(s):

Head And Neck ◽

Systematic Reviews ◽

Meta Analysis ◽

Disease Free Survival ◽

Umbrella Review ◽

Prognostic Role ◽

Hazard Ratios ◽

Micro Rnas

We conducted an umbrella review which synthetizes the findings of systematic reviews available in the literature that investigate the prognostic role of miRNAs as potential biomarkers in the field of tertiary prevention of head and neck Cancer (HNC). We selected systematic reviews in English related to HNC, with meta-analysis of observational studies that reported quantitative prognostic measures, hazard ratios (HRs), overall survival (OS) or disease-free survival (DFS). The methodological quality of the included reviews was assessed by using the AMSTAR-2 tool. The most reported miRNAs were the following: miRNA2, Let7 family and miR17, etc. Four out of six reviews particularly emphasized the link between miRNA21 expression and HNC patients. Recently the cumulative effects of sets of miRNAs have been increasingly studied and might be a stronger predictor of survival than single miRNA.

Download Full-text

Prognostic Role of MicroRNA 222 in Patients with Glioma: A Meta-analysis

BioMed Research International ◽

10.1155/2020/4689689 ◽

2020 ◽

Vol 2020 ◽

pp. 1-7

Author(s):

Yanlin Song ◽

Jing Zhang ◽

Min He ◽

Jianguo Xu

Keyword(s):

Overall Survival ◽

Meta Analysis ◽

Disease Free Survival ◽

Cochrane Library ◽

Data Sets ◽

Prognostic Role ◽

China National Knowledge Infrastructure ◽

Knowledge Infrastructure ◽

Hazard Ratios

Background. Several studies have focused on the prognostic role of microRNA 222 in glioma. But different conclusions were drawn by these studies. We aimed to systematically evaluate the role of microRNA 222 in glioma by conducting a meta-analysis. Methods. A systematic literature search until January 2020 was conducted in Web of Science, EMBASE, Cochrane Library, PubMed, and China National Knowledge Infrastructure. The general characteristics and relevant data of nine articles were extracted. Hazard ratios (HRs) with 95% confidence intervals (CIs) were applied to evaluate the prognostic role of microRNA 222 in glioma. The primary outcomes were overall survival (OS) and disease-free survival (DFS). Results. Nine articles (11 data sets) with 1564 patients were included. We systematically evaluated the role of microRNA 222 for OS and DFS in glioma patients (HR for OS=1.72; 95% CI, 1.31-2.26; p=0.001; HR for DFS=1.02; 95% CI, 0.86-1.22; p=0.032). Subgroup analyses were performed according to the sources of patients, the types of the samples, the stages of the tumors, the methods for detecting the microRNA 222, and the sample size. No significant publication bias was found. Conclusion. In conclusion, our study provided evidence that a high expression of microRNA 222 was related to worse overall survival in glioma patients. However, given the limited study number, more high-quality studies are warranted in the future.

Download Full-text